Stoke Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Stoke Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $84.22 million for the year ending 2025.

  • Stoke Therapeutics, Inc. showed a decrease of -34.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 20.1%.
  • Historical annual values: Fiscal year 2025: $84.22 million | Fiscal year 2024: $127.98 million | Fiscal year 2023: $191.44 million | Fiscal year 2022: $113.56 million | Fiscal year 2021: $144.90 million | Fiscal year 2020: $287.31 million | Fiscal year 2019: $222.47 million | Fiscal year 2018: $105.40 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: